

Bernhard Hemmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/471682/publications.pdf>

Version: 2024-02-01

401
papers

37,960
citations

3668

92
h-index

4414

178
g-index

439
all docs

439
docs citations

439
times ranked

37808
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1020-1027.	1.4	37
2	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2022, 28, 132-138.	1.4	31
3	Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2022, 28, 522-531.	1.4	24
4	Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. <i>Multiple Sclerosis Journal</i> , 2022, 28, 900-909.	1.4	4
5	COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	26
6	Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	13
7	Intrathecally Expanding B Cell Clones in Herpes Simplex Encephalitis: A Case Report. <i>Neurology and Therapy</i> , 2022, , 1.	1.4	2
8	A new form of axonal pathology in a spinal model of neuromyelitis optica. <i>Brain</i> , 2022, 145, 1726-1742.	3.7	10
9	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
10	Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	13
11	Association of pregnancies with risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1630-1640.	1.4	2
12	Cryptococcal Meningitis Reported With Fingolimod Treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	11
13	Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103728.	0.9	1
14	Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability. <i>NeuroImage: Clinical</i> , 2022, 34, 103006.	1.4	11
15	The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. <i>Neurology</i> , 2022, 99, .	1.5	21
16	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	4.9	23
17	P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica. <i>Neurotherapeutics</i> , 2022, 19, 1603-1616.	2.1	3
18	T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis. <i>Clinical Neuroradiology</i> , 2021, 31, 235-243.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. <i>Neurotherapeutics</i> , 2021, 18, 364-377.	2.1	20
20	Genetic Variation in <i>WNT9B</i> Increases Relapse Hazard in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 884-894.	2.8	12
21	Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	20
22	Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110227.	0.5	20
23	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	1.7	33
24	Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
25	Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. <i>Nature Immunology</i> , 2021, 22, 880-892.	7.0	34
26	The Aryl Hydrocarbon Receptor-Dependent TGF- β /VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	12
27	Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1042.	3.1	5
28	Ethical use of off-label disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1403-1410.	1.4	12
29	Association of peripapillary hyperreflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, .	1.7	9
30	Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. <i>Neurological Research and Practice</i> , 2021, 3, 45.	1.0	7
31	Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 2589-2597.	2.1	0
32	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
33	COVID-19-associated Large Vessel Stroke in a 28-year-old Patient. <i>Clinical Neuroradiology</i> , 2021, 31, 511-514.	1.0	9
34	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
35	Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	14
36	Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination. <i>Frontiers in Neurology</i> , 2021, 12, 820049.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. <i>Nature Communications</i> , 2020, 11, 157.	5.8	218
38	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	3.1	7
39	Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon- β , glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. <i>PLoS ONE</i> , 2020, 15, e0235449.	1.1	20
40	Vaccination in B-cell-depleted patients with multiple sclerosis. <i>Neurology</i> , 2020, 95, 613-614.	1.5	5
41	Code Stroke Patient Referral by Emergency Medical Services During the Public COVID-19 Pandemic Lockdown. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105175.	0.7	13
42	Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117090.	0.3	125
43	Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 606338.	2.2	42
44	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. <i>BMC Medicine</i> , 2020, 18, 298.	2.3	11
45	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	0.9	66
46	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	2.7	67
47	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	3.1	11
48	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
49	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
50	Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 2217-2224.	1.7	21
51	Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577.	1.8	64
52	DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. <i>PLoS Computational Biology</i> , 2020, 16, e1007616.	1.5	54
53	Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. <i>Journal of Neurology</i> , 2020, 267, 2307-2318.	1.8	23
54	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.5	45

#	ARTICLE	IF	CITATIONS
55	A call for a global COVID-19 Neuro Research Coalition. <i>Lancet Neurology</i> , The, 2020, 19, 482-484.	4.9	22
56	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	2.0	29
57	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
58	A large case-control study on vaccination as risk factor for multiple sclerosis. <i>Neurology</i> , 2019, 93, e908-e916.	1.5	31
59	The neuropathology of fatal encephalomyelitis in human Borna virus infection. <i>Acta Neuropathologica</i> , 2019, 138, 653-665.	3.9	57
60	Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?. <i>Brain and Behavior</i> , 2019, 9, e01417.	1.0	8
61	Isolation, Culture and Functional Characterization of Glia and Endothelial Cells From Adult Pig Brain. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 333.	1.8	13
62	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	6.0	710
63	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2019, 92, 151.2-151.	1.5	0
64	Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 124-129.	0.9	6
65	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
66	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87
67	CSF Protein Concentration Shows No Correlation With Brain Volume Measures. <i>Frontiers in Neurology</i> , 2019, 10, 463.	1.1	1
68	CSF parameters associated with early MRI activity in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e573.	3.1	18
69	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. <i>Nature Communications</i> , 2019, 10, 2236.	5.8	65
70	Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2019, 23, 101849.	1.4	60
71	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984709.	1.5	10
72	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	4.5	48

#	ARTICLE	IF	CITATIONS
73	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opinion on Biological Therapy, 2019, 19, 829-843.	1.4	34
74	Plasma Levels of Soluble A β 1-42 as a Biomarker for Alzheimer's Disease with Dementia. Journal of Alzheimer's Disease, 2019, 69, 83-90.	1.2	0
75	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	2.8	104
76	Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology, 2019, 291, 429-435.	3.6	46
77	Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. Journal of Neuroinflammation, 2019, 16, 219.	3.1	96
78	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	1.1	22
79	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	1.8	24
80	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Multiple Sclerosis Journal, 2019, 25, 565-573.	1.4	9
81	Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	1.4	12
82	Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 224-234.	1.4	104
83	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1071.	4.5	72
84	Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 90, e1815-e1821.	1.5	123
85	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	1.7	147
86	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	1.4	458
87	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	6.3	1,204
88	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	3.1	54
89	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	1.4	101
90	Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters. Multiple Sclerosis Journal, 2018, 24, 1115-1125.	1.4	36

#	ARTICLE	IF	CITATIONS
91	Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. <i>Journal of Autoimmunity</i> , 2018, 88, 83-90.	3.0	11
92	A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015. <i>Frontiers in Neurology</i> , 2018, 9, 871.	1.1	33
93	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	3.1	173
94	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
95	Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. <i>Nature Immunology</i> , 2018, 19, 1341-1351.	7.0	82
96	Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876719.	0.5	18
97	DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. <i>Nature Communications</i> , 2018, 9, 2397.	5.8	147
98	Monocyte NOTCH2 expression predicts IFN- γ immunogenicity in multiple sclerosis patients. <i>JCI Insight</i> , 2018, 3, .	2.3	46
99	Immune-directed therapies in MS – efficacy and limitations. <i>Nature Reviews Neurology</i> , 2017, 13, 72-74.	4.9	10
100	Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 847.	4.5	38
101	The spectrum of aseptic central nervous system infections in southern Germany – demographic, clinical and laboratory findings. <i>European Journal of Neurology</i> , 2017, 24, 1062-1070.	1.7	17
102	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
103	CNS Aquaporin-4-specific B cells connect with multiple B cell compartments in neuromyelitis optica spectrum disorder. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 369-380.	1.7	53
104	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
105	Daclizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 747-753.	1.4	4
106	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
107	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
108	Cortical pathology in multiple sclerosis detected by the χ^2 -weighted ratio from routine magnetic resonance imaging. <i>Annals of Neurology</i> , 2017, 82, 519-529.	2.8	102

#	ARTICLE	IF	CITATIONS
109	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , 2017, 16, 797-812.	4.9	397
110	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
111	Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. <i>Nature Immunology</i> , 2017, 18, 74-85.	7.0	311
112	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
113	Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients. <i>PLoS ONE</i> , 2017, 12, e0179590.	1.1	53
114	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017, 12, e0170395.	1.1	34
115	From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. <i>Current Neuropharmacology</i> , 2017, 15, 874-891.	1.4	40
116	Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e208.	3.1	9
117	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1089.	4.5	92
118	Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome. <i>Journal of Neurology</i> , 2016, 263, 2105-2113.	1.8	17
119	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. <i>Acta Neuropathologica</i> , 2016, 132, 413-431.	3.9	26
120	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016, 87, 978-987.	1.5	109
121	In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. <i>Annals of Neurology</i> , 2016, 79, 794-805.	2.8	45
122	Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. <i>Brain</i> , 2016, 139, 2855-2863.	3.7	95
123	Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. <i>NeuroImage</i> , 2016, 142, 188-197.	2.1	81
124	PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?. <i>Neurology</i> , 2016, 87, 440-441.	1.5	45
125	HLA Genetic Risk Burden in Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1500.	4.5	8
126	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016, 92, 333-335.	3.8	24

#	ARTICLE	IF	CITATIONS
127	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133
128	Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity. <i>Journal of Neurology</i> , 2016, 263, 1495-1502.	1.8	91
129	Spontaneous Cerebrospinal Fluid Leak With Venous Engorgement Mimicking a Contrast-Enhancing Cervical Mass. <i>JAMA Neurology</i> , 2016, 73, 886.	4.5	1
130	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36
131	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
132	B cell-directed therapies in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2016, 6, 37-47.	1.2	30
133	Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. <i>Multiple Sclerosis Journal</i> , 2016, 22, 893-900.	1.4	74
134	Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1192-1201.	1.4	21
135	Prevalence of neuropathic pain in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1224-1230.	1.4	47
136	Predictive value of transcranial evoked potentials during mechanical endovascular therapy for acute ischaemic stroke: a feasibility study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 598-603.	0.9	18
137	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
138	Extensive Recruitment of Plasma Blasts to the Cerebrospinal Fluid in Toscana Virus Encephalitis. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv124.	0.4	3
139	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. <i>Experimental Neurology</i> , 2015, 265, 8-21.	2.0	59
140	Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 93-108.	1.3	16
141	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
142	Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. <i>Journal of Autoimmunity</i> , 2015, 56, 34-44.	3.0	46
143	Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologiesâ€”conflicting results?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 537-539.	1.4	9
144	Dimethyl fumarate in relapsingâ€”remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 339-346.	1.4	69

#	ARTICLE	IF	CITATIONS
145	The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. <i>Journal of Neuroinflammation</i> , 2015, 12, 19.	3.1	48
146	Role of the innate and adaptive immune responses in the course of multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 406-419.	4.9	455
147	B lymphocytes in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e104.	3.1	132
148	Class II HLA interactions modulate genetic risk for multiple sclerosis. <i>Nature Genetics</i> , 2015, 47, 1107-1113.	9.4	312
149	Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 875-884.	1.4	50
150	Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. <i>Multiple Sclerosis Journal</i> , 2015, 21, 666-668.	1.4	6
151	Mobilization of CD133+ Progenitor Cells in Patients with Acute Cerebral Infarction. <i>PLoS ONE</i> , 2014, 9, e70796.	1.1	8
152	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2014, 20, 882-888.	1.4	18
153	Biomarkers of treatment response in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 165-172.	1.4	13
154	Complex antibody profiling to predict clinical outcome in childhood ADS. <i>Neurology</i> , 2014, 83, 2200-2201.	1.5	0
155	Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. <i>Neurology</i> , 2014, 82, 470-473.	1.5	45
156	JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants. <i>PLoS Pathogens</i> , 2014, 10, e1004084.	2.1	49
157	The genetics of natalizumab hypersensitivity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e52.	3.1	2
158	Spinal cord atrophy in early Huntington's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 302-306.	1.7	3
159	Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 490-496.	1.7	23
160	Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. <i>Journal of Neurology</i> , 2014, 261, 130-143.	1.8	67
161	IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1. <i>Nature Communications</i> , 2014, 5, 3770.	5.8	90
162	To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 271-279.	1.4	41

#	ARTICLE	IF	CITATIONS
163	Imaging of pathological effects of aquaporin-4 specific antibodies ex vivo and in vivo. <i>Journal of Neuroimmunology</i> , 2014, 275, 100.	1.1	0
164	Sources and functional significance of IL-6 in shaping autoreactive T cell responses in the peripheral immune compartment and the CNS. <i>Journal of Neuroimmunology</i> , 2014, 275, 152.	1.1	0
165	Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. <i>American Journal of Pathology</i> , 2014, 184, 2420-2429.	1.9	8
166	Î±4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. <i>Acta Neuropathologica Communications</i> , 2014, 2, 27.	2.4	25
167	Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. <i>Annals of Neurology</i> , 2014, 75, 810-828.	2.8	41
168	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. <i>Clinical and Experimental Immunology</i> , 2014, 175, 397-407.	1.1	68
169	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014, 83, 1210-1216.	1.5	30
170	Novel monoclonal antibodies for therapy of multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 503-513.	1.4	12
171	Current and Future Therapies Targeting the Immune System in Multiple Sclerosis. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 276-296.	0.9	33
172	The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2013, 10, 67.	3.1	12
173	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 248.	4.5	13
174	Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. <i>Journal of Neuroimmunology</i> , 2013, 262, 19-26.	1.1	10
175	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	9.4	1,213
176	Hunting for autoantibodies in multiple sclerosis. <i>Neurology</i> , 2013, 81, 944-945.	1.5	3
177	Mitochondrial membrane protein associated neurodegeneration: A novel variant of neurodegeneration with brain iron accumulation. <i>Movement Disorders</i> , 2013, 28, 224-227.	2.2	162
178	Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. <i>European Journal of Immunology</i> , 2013, 43, 2078-2088.	1.6	18
179	Update on immunopathogenesis and immunotherapy in multiple sclerosis. <i>ImmunoTargets and Therapy</i> , 2013, 2, 21.	2.7	17
180	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology</i> , The, 2013, 12, 756-767.	4.9	205

#	ARTICLE	IF	CITATIONS
181	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. <i>American Journal of Human Genetics</i> , 2013, 92, 854-865.	2.6	164
182	Enriched CD161 ^{high} CCR6 ⁺ T Cells in the Cerebrospinal Fluid of Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 345.	4.5	69
183	Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab infusion group. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1213-1215.	1.4	11
184	Reply to Dr Pandey. <i>Annals of Neurology</i> , 2013, 73, 148-149.	2.8	0
185	Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1454-1461.	1.4	37
186	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1533-1538.	1.4	92
187	Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 86-94.	2.8	38
188	White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1485-1492.	1.4	49
189	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	1.4	133
190	Simultaneous Electroencephalographic and Functional Magnetic Resonance Imaging Indicate Impaired Cortical Top-Down Processing in Association with Anesthetic-induced Unconsciousness. <i>Anesthesiology</i> , 2013, 119, 1031-1042.	1.3	153
191	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1339.	1.0	14
192	MRI Plaque Imaging Detects Carotid Plaques with a High Risk for Future Cerebrovascular Events in Asymptomatic Patients. <i>PLoS ONE</i> , 2013, 8, e67927.	1.1	41
193	The Role of B Cells in Multiple Sclerosis. , 2013, , 95-114.		0
194	Anti-JC-virus antibody prevalence in a German MS cohort. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1054-1055.	1.4	13
195	Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?. <i>Neurology</i> , 2012, 78, 928-930.	1.5	40
196	Time to talk about timing – when to start, stop and change anti-migratory drugs in MS. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1514-1516.	1.4	2
197	Pearls & Oysters: Cerebral HSV-2 vasculitis presenting as hemorrhagic stroke followed by multifocal ischemia. <i>Neurology</i> , 2012, 78, e12-e15.	1.5	16
198	¹⁸ F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1269-1276.	2.8	36

#	ARTICLE	IF	CITATIONS
199	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , 2012, 79, 285-287.	1.5	47
200	Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1045-1049.	1.4	27
201	Spatiotemporal Reconfiguration of Large-Scale Brain Functional Networks during Propofol-Induced Loss of Consciousness. <i>Journal of Neuroscience</i> , 2012, 32, 12832-12840.	1.7	175
202	Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. <i>Current Pharmaceutical Design</i> , 2012, 18, 209-219.	0.9	48
203	Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 115-123.	13.9	314
204	TNF-alpha induced NF- κ B signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. <i>Cytokine</i> , 2012, 57, 269-275.	1.4	96
205	Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. <i>Cytokine</i> , 2012, 58, 231-237.	1.4	5
206	CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. <i>Journal of Neuroinflammation</i> , 2012, 9, 93.	3.1	190
207	An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. <i>NeuroImage</i> , 2012, 59, 3774-3783.	2.1	972
208	Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon- β therapy in multiple sclerosis patients. <i>Pharmacogenomics Journal</i> , 2012, 12, 238-245.	0.9	43
209	Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2012, 112, 307-309.	0.5	1
210	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	3.1	593
211	Clinicopathological considerations in acute disseminated encephalomyelitis (ADEM): a fulminant case with favorable outcome. <i>Journal of Neurology</i> , 2012, 259, 753-755.	1.8	2
212	The role of the Epstein-Barr Virus receptor CD21 in Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 242, 47-51.	1.1	7
213	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
214	The role of antibodies in multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 239-245.	1.8	96
215	Interictal alterations of cytokines and leukocytes in patients with active epilepsy. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 423-428.	2.0	66
216	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-9.	0.4	52

#	ARTICLE	IF	CITATIONS
217	Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica. PLoS ONE, 2011, 6, e16083.	1.1	54
218	No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 264-5.	4.9	2
219	Thyroid antibodies in aquaporin-4 antibody positive central nervous system autoimmunity and multiple sclerosis. Clinical Endocrinology, 2011, 75, 271-272.	1.2	6
220	More CLEC16A gene variants associated with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 400-406.	1.0	24
221	EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. European Journal of Human Genetics, 2011, 19, 465-471.	1.4	74
222	The increasing incidence and prevalence of female multiple sclerosis – A critical analysis of potential environmental factors. Autoimmunity Reviews, 2011, 10, 495-502.	2.5	174
223	A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1428-1437.	1.9	3
224	Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology, 2011, 258, 1747-1762.	1.8	47
225	Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. Journal of Neuroinflammation, 2011, 8, 146.	3.1	68
226	Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide. Journal of Neuroinflammation, 2011, 8, 59.	3.1	3
227	Myoclonus and dystonia in 18p deletion syndrome. Movement Disorders, 2011, 26, 560-561.	2.2	17
228	Natalizumab and primary central nervous system lymphoma revisited. Annals of Neurology, 2011, 69, 1061-1062.	2.8	1
229	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology, 2011, 70, 520-520.	2.8	53
230	Systemic Thrombolysis in Ischemic Stroke After Recent Oral Surgery and Management of Oral Cavity Bleeding. Annals of Emergency Medicine, 2011, 57, 517-519.	0.3	4
231	Th17 lymphocytes traffic to the central nervous system independently of $\alpha 4$ integrin expression during EAE. Journal of Experimental Medicine, 2011, 208, 2465-2476.	4.2	241
232	Sibling disability risk at onset and during disease progression in familial multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1060-1066.	1.4	5
233	Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis. Archives of Neurology, 2011, 68, 480.	4.9	51
234	Dynamics of Intracranial Venous Flow Patterns in Patients with Idiopathic Intracranial Hypertension. European Neurology, 2011, 66, 334-338.	0.6	19

#	ARTICLE	IF	CITATIONS
235	Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. <i>Neurology</i> , 2011, 76, 1310-1315.	1.5	270
236	Role of statins in the treatment of multiple sclerosis: an update. <i>Neurodegenerative Disease Management</i> , 2011, 1, 109-114.	1.2	1
237	Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. <i>Neurology</i> , 2011, 76, 1214-1221.	1.5	146
238	Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta. <i>Archives of Neurology</i> , 2010, 67, 1095-101.	4.9	23
239	Î³Î´ T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism. <i>Immunity</i> , 2010, 33, 351-363.	6.6	246
240	The radiologically isolated syndrome: take action when the unexpected is uncovered?. <i>Journal of Neurology</i> , 2010, 257, 1602-1611.	1.8	36
241	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 740-750.	4.9	188
242	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
243	Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 219, 1-7.	1.1	82
244	The antibody response to oligodendrocyte specific protein in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 221, 81-86.	1.1	9
245	Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 227, 162-166.	1.1	69
246	Prognostic value of the ABCD2score beyond short-term follow-up after transient ischemic attack (TIA) - a cohort study. <i>BMC Neurology</i> , 2010, 10, 50.	0.8	18
247	Acyclovir resistance in herpes simplex encephalitis. <i>Annals of Neurology</i> , 2010, 67, 830-833.	2.8	58
248	MRI plaque imaging reveals high-risk carotid plaques especially in diabetic patients irrespective of the degree of stenosis. <i>BMC Medical Imaging</i> , 2010, 10, 27.	1.4	38
249	Patent foramen ovale is not associated with an increased risk of stroke recurrence. <i>European Journal of Neurology</i> , 2010, 17, 1339-1345.	1.7	16
250	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010, 17, 1019-1032.	1.7	376
251	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. <i>Genes and Immunity</i> , 2010, 11, 397-405.	2.2	70
252	Boxing. <i>Deutsches A&#x0308;rztblatt International</i> , 2010, 107, 835-9.	0.6	55

#	ARTICLE	IF	CITATIONS
253	Short commentary on a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking™. <i>Multiple Sclerosis Journal</i> , 2010, 16, 129-132.	1.4	7
254	Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. <i>Neurology</i> , 2010, 74, 1711-1715.	1.5	54
255	Natalizumab and Progressive Multifocal Leukoencephalopathy. <i>Archives of Neurology</i> , 2010, 67, 923-30.	4.9	105
256	EASY-HIT: HIV Full-Replication Technology for Broad Discovery of Multiple Classes of HIV Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5257-5268.	1.4	35
257	Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1189-1192.	1.4	24
258	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
259	Active Immunization with Amyloid- β 1-42 Impairs Memory Performance through TLR2/4-Dependent Activation of the Innate Immune System. <i>Journal of Immunology</i> , 2010, 185, 6338-6347.	0.4	61
260	Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. <i>Neurology</i> , 2010, 74, 1127-1135.	1.5	172
261	Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. <i>Brain</i> , 2010, 133, 375-388.	3.7	36
262	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2010, 67, 1201-8.	4.9	82
263	Translational Research in Neurology and Neuroscience 2010. <i>Archives of Neurology</i> , 2010, 67, 1307-15.	4.9	11
264	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. <i>Neurochemistry International</i> , 2010, 57, 662-667.	1.9	15
265	The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. <i>Journal of Autoimmunity</i> , 2010, 34, 371-379.	3.0	121
266	The Combination of Interferon- β and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 362-373.	1.9	26
267	Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease. <i>PLoS ONE</i> , 2010, 5, e16009.	1.1	24
268	Cooperation of B Cells and T Cells in the Pathogenesis of Multiple Sclerosis. <i>Results and Problems in Cell Differentiation</i> , 2009, 51, 115-126.	0.2	44
269	Should we measure the bioavailability of interferon β in vivo in patients with multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2009, 5, 126-127.	4.9	3
270	Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. <i>Neurology</i> , 2009, 72, 396-401.	1.5	128

#	ARTICLE	IF	CITATIONS
271	Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 259-61.	4.9	38
272	Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab. <i>Archives of Neurology</i> , 2009, 66, 1016-20.	4.9	66
273	INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS. <i>Neurology</i> , 2009, 73, 900-902.	1.5	3
274	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009, 73, 1914-1922.	1.5	653
275	Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 1216.	4.9	37
276	Cerebrospinal fluid biomarkers in multiple sclerosis. <i>Neurobiology of Disease</i> , 2009, 35, 117-127.	2.1	104
277	Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. <i>Annals of Neurology</i> , 2009, 65, 474-479.	2.8	52
278	Primary central nervous system lymphoma in a patient treated with natalizumab. <i>Annals of Neurology</i> , 2009, 66, 403-406.	2.8	78
279	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. <i>Annals of Neurology</i> , 2009, 66, 617-629.	2.8	516
280	Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. <i>Annals of Neurology</i> , 2009, 66, 833-842.	2.8	283
281	High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. <i>Journal of Neurology</i> , 2009, 256, 783-791.	1.8	26
282	Free caspase activity in CSF of patients with dementia. <i>Journal of Neurology</i> , 2009, 256, 1561-1562.	1.8	4
283	The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy. <i>Neurochemical Research</i> , 2009, 34, 1969-1974.	1.6	12
284	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , 2009, 16, 760.	1.7	73
285	Lesion patterns in patients with cryptogenic stroke with and without right-to-left shunt. <i>European Journal of Neurology</i> , 2009, 16, 1077-1082.	1.7	23
286	Etiology and site of temporal lobe epilepsy influence postictal cytokine release. <i>Epilepsy Research</i> , 2009, 86, 82-88.	0.8	108
287	Surface expression of CXCR4 on circulating CD133+ progenitor cells is associated with plaque instability in subjects with carotid artery stenosis. <i>Journal of Angiogenesis Research</i> , 2009, 1, 10.	2.9	8
288	The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 525.	1.0	77

#	ARTICLE	IF	CITATIONS
289	Cerebral vasculitis mimicking migraine with aura in a patient with Crohn's disease. <i>Acta Neurologica Belgica</i> , 2009, 109, 44-8.	0.5	10
290	Lack of association between right-to-left shunt and cerebral ischemia after adjustment for gender and age. <i>Journal of Negative Results in BioMedicine</i> , 2008, 7, 7.	1.4	7
291	HLA-DRB1*0401 and HLA-DRB1*0408 Are Strongly Associated with the Development of Antibodies against Interferon- β Therapy in Multiple Sclerosis. <i>American Journal of Human Genetics</i> , 2008, 83, 219-227.	2.6	114
292	HLA-DRB10401 and HLA-DRB10408 Are Strongly Associated with the Development of Antibodies against Interferon- β Therapy in Multiple Sclerosis. <i>American Journal of Human Genetics</i> , 2008, 83, 541.	2.6	0
293	F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. <i>Clinical Immunology</i> , 2008, 127, S54-S55.	1.4	0
294	Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. <i>Clinical Immunology</i> , 2008, 128, 306-313.	1.4	13
295	Pharmacological Treatment of Early Multiple Sclerosis. <i>Drugs</i> , 2008, 68, 73-83.	4.9	41
296	Disease-Modifying Agents for Multiple Sclerosis. <i>Drugs</i> , 2008, 68, 2445-2468.	4.9	63
297	Effects of interferon- β on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon- β treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 166-176.	1.4	45
298	NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. <i>Experimental Neurology</i> , 2008, 211, 370-377.	2.0	72
299	Analysis of the Stathmin rs182455 Single Nucleotide Promoter Polymorphism in Patients with Multiple Sclerosis. <i>Journal of Neurogenetics</i> , 2008, 22, 181-186.	0.6	3
300	Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1527.	4.9	40
301	Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. <i>Archives of Neurology</i> , 2008, 65, 1596.	4.9	179
302	Immunopathogenesis of Multiple Sclerosis. , 2007, , 197-204.		1
303	Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. <i>Brain</i> , 2007, 130, 2186-2198.	3.7	47
304	Revised criteria for neuromyelitis optica—a new diagnostic standard?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 132-133.	2.7	7
305	Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy. <i>Archives of Neurology</i> , 2007, 64, 169.	4.9	65
306	Acute disseminated encephalomyelitis: an acute hit against the brain. <i>Current Opinion in Neurology</i> , 2007, 20, 247-254.	1.8	116

#	ARTICLE	IF	CITATIONS
307	HIV hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels. <i>Aids</i> , 2007, 21, 253-255.	1.0	14
308	Treatment and treatment trials in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2007, 20, 286-293.	1.8	43
309	High Incidence of Post-Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes. <i>Archives of Neurology</i> , 2007, 64, 1055.	4.9	2
310	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 342-349.	4.0	56
311	Immunopathogenesis of Multiple Sclerosis: Overview. , 2007, , 171-187.		0
312	Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. <i>Annals of Neurology</i> , 2007, 62, 458-467.	2.8	29
313	Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. <i>Annals of Neurology</i> , 2007, 62, 314-326.	2.8	64
314	Clonal expansions of CD4+ B _h helper T cells in autoimmune myasthenia gravis. <i>European Journal of Immunology</i> , 2007, 37, 849-863.	1.6	41
315	The p150 subunit of dynactin (DCTN1) gene in the multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 231-234.	1.0	5
316	CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. <i>Journal of Neuroimmunology</i> , 2007, 190, 72-79.	1.1	115
317	Neutralising antibodies to interferon β in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 827-837.	1.8	48
318	Identification of Target Antigens in CNS Inflammation by Protein Array Technique. , 2007, , 137-148.		0
319	Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. <i>Brain</i> , 2006, 129, 200-211.	3.7	485
320	Immunopathogenesis and immunotherapy of multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 201-211.	2.7	224
321	Central nervous system infections a potential complication of systemic immunotherapy. <i>Current Opinion in Neurology</i> , 2006, 19, 271-276.	1.8	22
322	High throughput analysis of TCR β rearrangement and gene expression in single T cells. <i>Laboratory Investigation</i> , 2006, 86, 314-321.	1.7	19
323	A 32-year-old man with relapsing-progressive brainstem symptoms. <i>Lancet Neurology</i> , The, 2006, 5, 97-102.	4.9	7
324	Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist a putative role for substance P in CNS inflammation. <i>Journal of Neuroimmunology</i> , 2006, 179, 1-8.	1.1	41

#	ARTICLE	IF	CITATIONS
325	Accumulation of class switched IgD ⁺ IgM ⁺ memory B cells in the cerebrospinal fluid during neuroinflammation. <i>Journal of Neuroimmunology</i> , 2006, 180, 33-39.	1.1	55
326	Immune surveillance in multiple sclerosis patients treated with natalizumab. <i>Annals of Neurology</i> , 2006, 59, 743-747.	2.8	414
327	Lack of association with TorsinA haplotype in German patients with sporadic dystonia. <i>Neurology</i> , 2006, 66, 951-952.	1.5	43
328	Altered CD4 ⁺ /CD8 ⁺ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 1383.	4.9	271
329	Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19057-19062.	3.3	213
330	Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1037-1044.	3.9	98
331	Multiple sclerosis – novel insights and new therapeutic strategies. <i>Current Opinion in Neurology</i> , 2005, 18, 211-220.	1.8	34
332	Characterizing the Mechanisms of Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1345.	4.9	105
333	Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 403-412.	4.9	77
334	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. <i>Journal of Neuroimmunology</i> , 2005, 168, 128-137.	1.1	60
335	Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 165, 161-165.	1.1	25
336	High level of cross-reactivity in influenza virus hemagglutinin-specific CD4 ⁺ T-cell response: Implications for the initiation of autoimmune response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 169, 31-38.	1.1	50
337	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. <i>Annals of Neurology</i> , 2005, 58, 50-57.	2.8	203
338	Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, v30-v37.	1.8	12
339	Acute Disseminated Encephalomyelitis. <i>Archives of Neurology</i> , 2005, 62, 1673.	4.9	348
340	Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1620-3.	4.9	124
341	Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. <i>Brain</i> , 2005, 128, 1667-1676.	3.7	331
342	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2005, 115, 1352-1360.	3.9	248

#	ARTICLE	IF	CITATIONS
343	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2005, 115, 1352-1360.	3.9	154
344	Multiple Sclerosis - A Coordinated Immune Attack Across the Blood Brain Barrier. <i>Current Neurovascular Research</i> , 2004, 1, 141-150.	0.4	38
345	Recommendations for the Calculation of the Total Disturbing Return Current From Electric Traction Vehicles. <i>IEEE Transactions on Power Delivery</i> , 2004, 19, 1190-1197.	2.9	29
346	Viral Pathogens in Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 1500.	4.9	13
347	Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. <i>Tissue Antigens</i> , 2004, 64, 70-73.	1.0	12
348	The role of the Polio Virus Receptor and the Herpesvirus entry mediator B genes for the development of MS. <i>Journal of Neuroimmunology</i> , 2004, 156, 171-177.	1.1	9
349	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. <i>Acta Neuropathologica</i> , 2004, 107, 575-577.	3.9	16
350	Escalating immunotherapy of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1329-1339.	1.8	129
351	Myositis in a patient with large granular leukocyte leukemia. <i>Muscle and Nerve</i> , 2004, 29, 873-877.	1.0	8
352	Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. <i>Muscle and Nerve</i> , 2004, 30, 131-156.	1.0	185
353	Gene expression profiles derived from single cells in human postmortem brain. <i>Brain Research Protocols</i> , 2004, 13, 18-25.	1.7	20
354	Specificity and degeneracy: T cell recognition in CNS autoimmunity. <i>Molecular Immunology</i> , 2004, 40, 1057-1061.	1.0	8
355	Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. <i>American Journal of Ophthalmology</i> , 2004, 138, 439-443.	1.7	7
356	New immunopathologic insights into multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 246-255.	2.0	27
357	TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. <i>Nature Immunology</i> , 2003, 4, 248-254.	7.0	426
358	Clonal Accumulation of Activated CD8+T Cells in the Central Nervous System during the Early Phase of Neuroborreliosis. <i>Journal of Infectious Diseases</i> , 2003, 187, 963-973.	1.9	27
359	CD45 Isoform Expression in Autoimmune Myasthenia Gravis. <i>Autoimmunity</i> , 2003, 36, 117-121.	1.2	17
360	The Immune Response at Onset and During Recovery From <i>Borrelia burgdorferi</i> Meningoradiculitis. <i>Archives of Neurology</i> , 2003, 60, 849.	4.9	69

#	ARTICLE	IF	CITATIONS
361	Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. <i>Brain</i> , 2002, 125, 538-550.	3.7	235
362	Pathogenesis of multiple sclerosis: an update on immunology. <i>Current Opinion in Neurology</i> , 2002, 15, 227-231.	1.8	116
363	Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease. <i>Annals of Neurology</i> , 2002, 52, 253-256.	2.8	152
364	Effect of minocycline in experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2002, 52, 689-690.	2.8	47
365	A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. <i>Immunogenetics</i> , 2002, 54, 158-163.	1.2	35
366	New concepts in the immunopathogenesis of multiple sclerosis. <i>Nature Reviews Neuroscience</i> , 2002, 3, 291-301.	4.9	517
367	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. <i>Journal of Autoimmunity</i> , 2001, 16, 187-192.	3.0	61
368	Immunosuppressive Treatment of Ocular Myasthenia Gravis. <i>BioDrugs</i> , 2001, 15, 369-378.	2.2	18
369	New approaches to dissect degeneracy and specificity in T cell antigen recognition. <i>Journal of Molecular Medicine</i> , 2001, 79, 358-367.	1.7	14
370	No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001, 118, 300-303.	1.1	8
371	Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. <i>Brain</i> , 2001, 124, 2169-2176.	3.7	210
372	Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands. <i>Journal of Immunology</i> , 2001, 167, 2130-2141.	0.4	97
373	Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells. , 2000, 59, 86-93.		14
374	A point mutation in PTPRC is associated with the development of multiple sclerosis. <i>Nature Genetics</i> , 2000, 26, 495-499.	9.4	197
375	Degeneracy in T-cell antigen recognition â€” implications for the pathogenesis of autoimmune diseases. <i>Journal of Neuroimmunology</i> , 2000, 107, 148-153.	1.1	18
376	Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor $V\beta$ analysis. <i>Journal of Immunological Methods</i> , 2000, 246, 131-143.	0.6	42
377	Minimal peptide length requirements for CD4+ T cell clonesâ€”implications for molecular mimicry and T cell survival. <i>International Immunology</i> , 2000, 12, 375-383.	1.8	70
378	Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency. <i>Journal of Immunology</i> , 2000, 164, 861-871.	0.4	64

#	ARTICLE	IF	CITATIONS
379	Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. <i>Nature Medicine</i> , 1999, 5, 1375-1382.	15.2	216
380	Molecular mimicry and multiple sclerosis: Degenerate T-cell recognition and the induction of autoimmunity. <i>Annals of Neurology</i> , 1999, 45, 559-567.	2.8	98
381	Stress doses of hydrocortisone reverse hyperdynamic septic shock. <i>Critical Care Medicine</i> , 1999, 27, 723-732.	0.4	941
382	From specificity to degeneracy to molecular mimicry: antigen recognition of human autoreactive and pathogen-specific CD4+ T cells. , 1999, , 21-28.		0
383	Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. <i>Journal of Immunology</i> , 1999, 162, 2073-80.	0.4	88
384	Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. <i>Journal of Immunology</i> , 1999, 163, 6424-34.	0.4	48
385	MRI of spinal cord and brain lesions in subacute combined degeneration. <i>Neuroradiology</i> , 1998, 40, 716-719.	1.1	82
386	Probing degeneracy in T-cell recognition using peptide combinatorial libraries. <i>Trends in Immunology</i> , 1998, 19, 163-168.	7.5	133
387	Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. <i>Journal of Neuroimmunology</i> , 1998, 87, 203-209.	1.1	59
388	Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 822-827.	0.9	198
389	The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. <i>Chemical Biology and Drug Design</i> , 1998, 52, 338-345.	1.2	24
390	Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. <i>Journal of Immunology</i> , 1998, 160, 3631-6.	0.4	103
391	Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. <i>Journal of Immunology</i> , 1998, 160, 5807-14.	0.4	119
392	Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II α -restricted T Cell Clone. <i>Journal of Experimental Medicine</i> , 1997, 185, 1651-1660.	4.2	313
393	Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype. <i>Neurology</i> , 1997, 49, 1116-1126.	1.5	40
394	T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. <i>Journal of Neuroimmunology</i> , 1997, 77, 195-203.	1.1	58
395	Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. <i>Journal of Immunology</i> , 1997, 158, 2756-61.	0.4	66
396	Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. <i>Journal of Immunology</i> , 1997, 158, 3746-52.	0.4	52

#	ARTICLE	IF	CITATIONS
397	Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. <i>Journal of Immunology</i> , 1997, 159, 1520-9.	0.4	35
398	Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). <i>European Journal of Immunology</i> , 1996, 26, 2624-2634.	1.6	96
399	Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7. , 1996, 45, 820-828.		16
400	Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). , 1996, 45, 852-862.		41
401	Restless legs syndrome after a borrelia-induced myelitis. <i>Movement Disorders</i> , 1995, 10, 521-522.	2.2	26